| Louis J Vaickus, MD, PHD | |
|
1 Medical Center Dr, Pathology, Lebanon, NH 03756-1000 | |
| (603) 650-8693 | |
| Not Available |
| Full Name | Louis J Vaickus |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 12 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841551843 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Androscoggin Valley Hospital | Berlin, NH | Hospital |
| Southwestern Vermont Medical Center | Bennington, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
News Archive
Major depression (MD) and alcohol dependence (AD) co-occur in individuals and within families at higher rates than expected by chance. This study looked at how mood-related drinking motives may explain the overlapping familial risk for MD and AD. Findings suggest that individuals with strong mood-related drinking motives, especially those based on negative feelings, may be vulnerable to developing both MD and AD.
By inspecting the sequence of all 3 billion "letters" that make up the genome of a single person affected with a rare, inherited disorder, a Johns Hopkins and Duke University team ferreted out the single genetic mutation that accounts for the disease.
Children and young adult thyroid cancer patients who are treated with radioactive iodine have an elevated risk of developing a second primary malignancy, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).
When the National Institute of Standards and Technology issued the world's first standardized monoclonal antibody in July 2016, the exhaustively analyzed protein known as NISTmAb was intended as a valuable tool for biopharmaceutical companies.
› Verified 6 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Major depression (MD) and alcohol dependence (AD) co-occur in individuals and within families at higher rates than expected by chance. This study looked at how mood-related drinking motives may explain the overlapping familial risk for MD and AD. Findings suggest that individuals with strong mood-related drinking motives, especially those based on negative feelings, may be vulnerable to developing both MD and AD.
By inspecting the sequence of all 3 billion "letters" that make up the genome of a single person affected with a rare, inherited disorder, a Johns Hopkins and Duke University team ferreted out the single genetic mutation that accounts for the disease.
Children and young adult thyroid cancer patients who are treated with radioactive iodine have an elevated risk of developing a second primary malignancy, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).
When the National Institute of Standards and Technology issued the world's first standardized monoclonal antibody in July 2016, the exhaustively analyzed protein known as NISTmAb was intended as a valuable tool for biopharmaceutical companies.
› Verified 6 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Major depression (MD) and alcohol dependence (AD) co-occur in individuals and within families at higher rates than expected by chance. This study looked at how mood-related drinking motives may explain the overlapping familial risk for MD and AD. Findings suggest that individuals with strong mood-related drinking motives, especially those based on negative feelings, may be vulnerable to developing both MD and AD.
By inspecting the sequence of all 3 billion "letters" that make up the genome of a single person affected with a rare, inherited disorder, a Johns Hopkins and Duke University team ferreted out the single genetic mutation that accounts for the disease.
Children and young adult thyroid cancer patients who are treated with radioactive iodine have an elevated risk of developing a second primary malignancy, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).
When the National Institute of Standards and Technology issued the world's first standardized monoclonal antibody in July 2016, the exhaustively analyzed protein known as NISTmAb was intended as a valuable tool for biopharmaceutical companies.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Louis J Vaickus, MD, PHD 1 Medical Center Dr, Pathology, Lebanon, NH 03756-1000 Ph: (603) 650-8693 | Louis J Vaickus, MD, PHD 1 Medical Center Dr, Pathology, Lebanon, NH 03756-1000 Ph: (603) 650-8693 |
News Archive
Major depression (MD) and alcohol dependence (AD) co-occur in individuals and within families at higher rates than expected by chance. This study looked at how mood-related drinking motives may explain the overlapping familial risk for MD and AD. Findings suggest that individuals with strong mood-related drinking motives, especially those based on negative feelings, may be vulnerable to developing both MD and AD.
By inspecting the sequence of all 3 billion "letters" that make up the genome of a single person affected with a rare, inherited disorder, a Johns Hopkins and Duke University team ferreted out the single genetic mutation that accounts for the disease.
Children and young adult thyroid cancer patients who are treated with radioactive iodine have an elevated risk of developing a second primary malignancy, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).
When the National Institute of Standards and Technology issued the world's first standardized monoclonal antibody in July 2016, the exhaustively analyzed protein known as NISTmAb was intended as a valuable tool for biopharmaceutical companies.
› Verified 6 days ago
Dr. Charles Harker Rhodes Iii, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Department Of Pathology, Lebanon, NH 03756 Phone: 603-650-7744 | |
Dr. Zbigniew Macdonald Szczepiorkowski, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-653-9907 Fax: 603-650-4845 | |
Dr. Melissa Louise Petras, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Dr. Kim T Ornvold, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc - Dept Of Pathology, Lebanon, NH 03756 Phone: 603-650-7211 | |
Seth Charles Lummus, D.O. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7211 | |
Dr. Arief Suriawinata, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc - Pathology, Lebanon, NH 03756 Phone: 603-650-7048 | |
Elena Zarovnaya, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8458 |